The major factors that hinder growth of the U.S. opioids market include increased opioid abuse and side effects associated with opioids. For instance, according to the data provided by the National Institute on Drug Abuse, a U.S., federal government research institute, in January 2022, nearly 92,000 persons in the U.S. died from drug-involved overdose in 2020, including illicit drugs and prescription opioids.
Market Opportunities – Increasing Facility Expansion by Key Players
For instance, in February, 2023, Veranova, L.P.’s subsidiary, Macfarlan Smith Ltd., a global leader in process development and manufacturing of Codeine APIs, announced the facility expansion of its mid-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Edinburgh, U.K. facility to handle highly active APIs and intermediates, to enable growth in the generic opioid analgesic and anti-addiction markets.
U.S. Opioids Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients